Pernix Therapeutics (PTX) to Acquire Zogenix's (ZGNX) Zohydro ER Business

Go back to Pernix Therapeutics (PTX) to Acquire Zogenix's (ZGNX) Zohydro ER Business

Cantor Fitzgerald Downgrades Pernix Therapeutics (PTX) to Hold on Zohydro Deal

March 12, 2015 6:52 AM EDT

Cantor Fitzgerald downgraded Pernix Therapeutics (NASDAQ: PTX) from Buy to Hold with a price target of $11.00 (from $12.00) as they take a "wait and see" approach to Pernix's aggressive transformational pain deal.

Irina Rivkind Koffler said, "We model 33% EPS dilution in 2015 (but +16% accretion in... More

William Blair Downgrades Zogenix, Inc. (ZGNX) to Market Perform

March 11, 2015 7:08 AM EDT

William Blair downgraded Zogenix, Inc. (NASDAQ: ZGNX) from Outperform to Market Perform.

For an analyst ratings summary and ratings history on Zogenix, Inc. click here. For more ratings news on Zogenix, Inc. click here.

Shares of Zogenix, Inc. closed at $1.67 yesterday.

... More

Pernix Therapeutics (PTX) Bullish Stance Reiterated at Needham & Company Following Zohydro ER Deal

March 11, 2015 6:42 AM EDT

Needham & Company analyst Elliot Wilbur reiterated a Strong Buy rating and $16 price target on Pernix Therapeutics (NASDAQ: PTX) after the company announced purchase of Zohydro ER.

Wilbur commented, "PTX is back in deal mode, announcing the purchase of Zohydro ER, a marketed long-acting abuse... More